UroGen Pharma prices $107.5M public offering of 5M shares at $17.50, plus pre-funded warrants

UroGen Pharma Ltd.

Offering: 5,000,000 ordinary shares at $17.50/share plus 1,142,857 pre-funded warrants at $17.499 each.
Gross proceeds expected to be approximately $107.5 million before underwriting discounts and expenses.
Underwriters granted a 30-day option to purchase up to an additional 921,428 ordinary shares.
Closing expected on June 20, 2024, subject to customary conditions.
TD Cowen and Guggenheim Securities are joint book-running managers; Oppenheimer & Co. is lead manager.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.